Q-omics provides the consensus-scored DNMT3B profile across patient tissues and cancer cell-line models. DNMT3B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DNMT3B is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, DNMT3B RNA expression shows 19,989 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where DNMT3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNMT3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNMT3B survival associations across molecular data types. DNMT3B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNMT3B RNA expression–survival associations across cancer types. High DNMT3B expression shows unfavorable associations in MESO, LIHC, ACC, KIRC and KIRP, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DNMT3B RNA expression.
This table summarizes DNMT3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DNMT3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNMT3B shows higher tumor expression in HNSC, BLCA, COAD, KIRP, LUAD and UCEC. The HNSC box plot shows higher DNMT3B RNA expression in tumor versus normal tissue (log2 FC = +1.833, t-test p < 0.001).
This table shows molecular features associated with DNMT3B in patient tissues and cancer cell lines. In patient samples, DNMT3B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNMT3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
